Robert Wallen
Psychiatric/Mental Health · Goodyear, AZNPI 1609583517
Payments from drug & device makers
Across 175 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$569
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$476
- Indivior Inc.$424
- Vanda Pharmaceuticals Inc.$395
- Alkermes, Inc.$224
- Braeburn Inc.$151
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,277100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 48 | $569 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $476 |
| Indivior Inc. | 17 | $424 |
| Vanda Pharmaceuticals Inc. | 18 | $395 |
| Alkermes, Inc. | 10 | $224 |
| Braeburn Inc. | 6 | $151 |
| Axsome Therapeutics, Inc. | 5 | $141 |
| Almatica Pharma LLC | 5 | $138 |
| Neurocrine Biosciences, Inc. | 5 | $131 |
| Teva Pharmaceuticals USA, Inc. | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 3 | $119 |
| Corium, LLC | 9 | $115 |
| Johnson & Johnson | 4 | $110 |
| Vertical Pharmaceuticals, LLC | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
How this compares
$3,277 in reported general payments places this provider in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 16 | $2,030 |
| Aripiprazole | 18 | $1,296 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $499 |
| Quetiapine Fumarate | 21 | $339 |
| Escitalopram Oxalate | 16 | $175 |
| Duloxetine Hcl | 12 | $160 |
| Trazodone Hcl | 20 | $137 |
| Fluoxetine Hcl | 15 | $123 |
| Lamotrigine | 26 | $122 |
| Clonazepam | 18 | $85 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Goodyear
- Elizabeth ElliottPhoenix$363K
- Diane StrickerGilbert$281K
- Russell HorningPhoenix$254K
- Stacy UnderwoodMesa$252K
- Angela ChenTempe$107K
- Brett LeifsonScottsdale$90K
- Claire ReecePhoenix$88K
- Bryan LazaroScottsdale$61K
- Luis FongPhoenix$59K
- Jeffrey EdelmanPeoria$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.